MedPath

A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD

Phase 2
Completed
Conditions
Neovascular Age-related Macular Degeneration
Registration Number
NCT01157715
Lead Sponsor
Chengdu Kanghong Biotech Co., Ltd.
Brief Summary

This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.

Detailed Description

AMD is the leading cause of severe vision loss in people over the age of 65 in the United States and other western countries. A quantity of documents indicate that neovascularization promoted by VEGF is main cause of visual acuity decline. Patients are starving for a new drug which can notably improve VA with less administration frequency and lower treatment cost.

The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The pre-clinical researches and phase I study show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF.

This study is designed to confirm the efficacy and safety of multiple injections of KH902 at variable dosing regimen in patients with CNV due to neovascular AMD. Based on the characteristics of KH902 and results from KH902 Phase I study as well as reference to clinical trials of similar drugs, it is determined that KH902 is administrated at 0.5mg/eye/time and 2.0mg/eye/time.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
122
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The incidence rate of adverse eventat 3-month
Change from baseline in BCVAat 3-month
Secondary Outcome Measures
NameTimeMethod
Change from baseline in central retinal thicknessat 3-month and 12-month

Trial Locations

Locations (9)

Optometry and Ophthalmology Hospital of Wenzhou Medical College

🇨🇳

Wenzhou, Fujian, China

Zhongshan Ophthalmic Center, Sun-Yat University

🇨🇳

Guangzhou, Guangdong, China

Second Affiliated Hospital of Xiangya Medical College

🇨🇳

Changsha, Hunan, China

Xijing Hosiptal of the Fourth Military Medical University

🇨🇳

Xian, Shanxi, China

Sichuan University West China Hospitcal

🇨🇳

Chengdu, Sichuan, China

Peking University People's Hospital

🇨🇳

Peking, China

PekingTongren Hospital

🇨🇳

Peking, China

Eye & ENT Hospital of Fudan University

🇨🇳

Shanghai, China

Shanghai First People's Hospital

🇨🇳

Shanghai, China

Optometry and Ophthalmology Hospital of Wenzhou Medical College
🇨🇳Wenzhou, Fujian, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.